FI4031569T3 - Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät - Google Patents
Kantasolutekijän vasta-aineet ja niiden käyttömenetelmätInfo
- Publication number
- FI4031569T3 FI4031569T3 FIEP20866530.7T FI20866530T FI4031569T3 FI 4031569 T3 FI4031569 T3 FI 4031569T3 FI 20866530 T FI20866530 T FI 20866530T FI 4031569 T3 FI4031569 T3 FI 4031569T3
- Authority
- FI
- Finland
- Prior art keywords
- antibody
- seq
- amino acid
- heavy chain
- light chain
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (8)
1. Vasta-aine, joka sitoutuu spesifisesti kan- tasolutekijään 248 (SCF248), jossa vasta-aine käsittää raskaanketjun CDR1:n, CDR2:n ja CDR3:n, jotka käsittävät järjestyksessä SEO ID NO:t: 1, 2 ja 3, ja kevytketjun CDR1:n, CDR2:n ja CDR3:n, jotka käsittävät järjestyk- sessä SEQ ID NO:t: 4, 5 ja 6, jossa vasta-aine on huma- nisoitu ja jossa vasta-aine käsittää: (a) raskaanketjun vaihtelevan alueen, jolla on SEO ID NO: 8:n mukainen aminohapposekvenssi; ja (b) kevytketjun vaihtelevan alueen, jolla on SEO ID NO: 16:n mukainen aminohapposekvenssi.
2. Patenttivaatimuksen 1 mukainen vasta-aine, jossa vasta-aine on monoklonaalinen vasta-aine.
3. Patenttivaatimuksen 2 mukainen vasta-aine, jossa vasta-aine käsittää: (a) raskaanketjun, joka on SEO ID NO: 42:n mu- kainen, ja kevytketjun, joka on SEO ID NO: 49:n mukai- nen; tai (b) raskaanketjun, joka on SEO ID NO: 43:n mu- kainen, ja kevytketjun, joka on SEO ID NO: 49:n mukai-
nen.
4. Patenttivaatimuksen 1-3 mukainen vasta- aine, jossa vasta-aine: (a) estää SCF:n ja c-Kitin välisen vuorovaiku- tuksen; (b) aiheuttaa SCF:n sisäistymisen; tai (c) ei sitoudu SCF220:een, tai mikä tahansa yhdistelmä (a)-(c):stä.
5. Eristetty nukleiinihappomolekyyli, joka koodaa jonkin patenttivaatimuksista 1-4 mukaista vasta- ainetta, ekspressiovektori, joka käsittää nukleiiniha- pon, joka koodaa jonkin patenttivaatimuksista 1-4 mu- kaista vasta-ainetta, tai rekombinantti isäntäsolu, joka käsittää ekspressiovektorin, joka käsittää nukle- iinihapon, joka koodaa jonkin patenttivaatimuksista 1- 4 mukaista vasta-ainetta.
6. Patenttivaatimuksen 2 mukainen vasta-aine, jossa monoklonaalinen vasta-aine käsittää ihmisen IgG4- domeenin.
7. Patenttivaatimuksen 6 mukainen vasta-aine, jossa ihmisen IgG4-domeeni käsittää S241P-mutaation aminohappotähteessä 241 ja L248E-mutaation aminohappo- tähteessä 248.
8. Patenttivaatimuksen 1 mukainen vasta-aine, joka käsittää: (i) raskaanketjun, joka käsittää SEO ID NO: 42:n mukaisen aminohapposekvenssin; ja (ii) kevytketjun, joka käsittää SEO ID NO: 49:n mukaisen aminohapposekvenssin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962900927P | 2019-09-16 | 2019-09-16 | |
| PCT/US2020/050973 WO2021055408A1 (en) | 2019-09-16 | 2020-09-16 | Anti-stem cell factor antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4031569T3 true FI4031569T3 (fi) | 2025-11-14 |
Family
ID=74868426
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20866530.7T FI4031569T3 (fi) | 2019-09-16 | 2020-09-16 | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US11939373B2 (fi) |
| EP (3) | EP4031176A4 (fi) |
| JP (4) | JP7698635B2 (fi) |
| KR (1) | KR20220079561A (fi) |
| CN (2) | CN114729036B (fi) |
| AR (1) | AR119979A1 (fi) |
| AU (2) | AU2020351138A1 (fi) |
| BR (1) | BR112022004776A2 (fi) |
| CA (2) | CA3154648A1 (fi) |
| CL (1) | CL2022000633A1 (fi) |
| CO (1) | CO2022003661A2 (fi) |
| DK (1) | DK4031569T3 (fi) |
| DO (1) | DOP2022000058A (fi) |
| EC (1) | ECSP22022676A (fi) |
| FI (1) | FI4031569T3 (fi) |
| IL (1) | IL291385A (fi) |
| MX (1) | MX2022003159A (fi) |
| PE (1) | PE20230090A1 (fi) |
| PH (1) | PH12022550647A1 (fi) |
| PT (1) | PT4031569T (fi) |
| SA (1) | SA522431966B1 (fi) |
| TW (2) | TWI875812B (fi) |
| UA (1) | UA129546C2 (fi) |
| UY (1) | UY38883A (fi) |
| WO (2) | WO2021055409A1 (fi) |
| ZA (1) | ZA202203272B (fi) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12133884B2 (en) | 2018-05-11 | 2024-11-05 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| DK4031569T3 (da) | 2019-09-16 | 2025-11-17 | Opsidio Llc | Antistoffer mod stamcellefaktor og fremgangsmåder til anvendelse deraf |
| KR20250167153A (ko) * | 2023-03-03 | 2025-11-28 | 셀덱스 쎄라퓨틱스, 인크. | 항-줄기 세포 인자(scf) 및 항-흉선 기질 림포포이에틴(tslp) 항체, 및 이중특이적 구축물 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7144731B2 (en) * | 1989-10-16 | 2006-12-05 | Amgen Inc. | SCF antibody compositions and methods of using the same |
| AU6541090A (en) * | 1989-10-16 | 1991-05-16 | Amgen, Inc. | Stem cell factor |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5911988A (en) | 1995-04-28 | 1999-06-15 | Bayer Corporation | Method for treating asthma using SCF antibody |
| JP3583214B2 (ja) | 1995-12-01 | 2004-11-04 | 株式会社ニチレイ | ヒトｓｃｆに対するモノクローナル抗体 |
| US20090087878A9 (en) | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US6399857B1 (en) * | 1999-09-22 | 2002-06-04 | Paradigm Genetics, Inc. | Modified nucleotide sequence encoding a LexA DNA binding domain optimized for arabidopsis species |
| AR037756A1 (es) * | 2001-12-17 | 2004-12-01 | Bayer Corp | Anticuerpo que inhibe la actividad del factor de las celulas precursoras y su uso para el tratamiento del asma. |
| US7902338B2 (en) * | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
| ZA200604620B (en) * | 2003-12-10 | 2007-10-31 | Medarex Inc | IP-10 antibodies and their uses |
| EP1745076B1 (en) * | 2004-04-29 | 2012-06-13 | Otsuka Pharmaceutical Co., Ltd. | Antibodies specific for glycoprotein vi and methods of producing these antibodies |
| WO2006002064A2 (en) | 2004-06-14 | 2006-01-05 | Aerovance, Inc. | Antibody inhibiting stem cell factor activity and use for treatment of asthma |
| US20080248050A1 (en) * | 2006-06-30 | 2008-10-09 | Uchicago Argonne, Llc | Meta-specific vaccine, method for treating patients immunized with meta-specific vaccine |
| EP2281004A4 (en) * | 2008-04-14 | 2012-02-15 | Proscan Rx Pharma Inc | PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
| KR102119187B1 (ko) * | 2011-01-10 | 2020-06-08 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 줄기 세포 인자 억제제 |
| US20150018408A1 (en) | 2013-07-10 | 2015-01-15 | The Regents Of The University Of Michigan | Therapeutic antibodies and uses thereof |
| KR101384360B1 (ko) * | 2012-05-04 | 2014-04-14 | 아주대학교산학협력단 | Ｓｃｆ 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
| SG11201500489YA (en) | 2012-07-25 | 2015-02-27 | Kolltan Pharmaceuticals Inc | Anti-kit antibodies and uses thereof |
| US10927153B1 (en) | 2015-05-20 | 2021-02-23 | University Of South Florida | Synthetic plasmodium antigens, compositions, and uses thereof |
| PE20240142A1 (es) * | 2015-08-19 | 2024-02-01 | Pfizer | Anticuerpos inhibidores via del factor tisular y usos de los mismos |
| KR20170022409A (ko) | 2015-08-20 | 2017-03-02 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| US11091559B2 (en) * | 2015-08-27 | 2021-08-17 | Celldex Therapeutics, Inc. | Anti-ALK antibodies and methods for use thereof |
| CA3009488A1 (en) * | 2015-12-22 | 2017-06-29 | Abbvie Stemcentrx Llc | Novel anti-upk1b antibodies and methods of use |
| SG11201900753VA (en) | 2016-10-05 | 2019-02-27 | Cellresearch Corp Pte Ltd | A method of isolating mesenchymal stem cells from umbilical cord amniotic membrane using a cell culture medium |
| WO2019066093A1 (ko) | 2017-09-26 | 2019-04-04 | 주식회사 와이바이오로직스 | Scf 특이적 항체 |
| WO2019088658A1 (ko) | 2017-10-31 | 2019-05-09 | 주식회사 컴워스파마 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| KR102131898B1 (ko) | 2017-10-31 | 2020-07-08 | 주식회사 노벨티노빌리티 | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 |
| US20210388073A1 (en) | 2018-10-19 | 2021-12-16 | The General Hospital Corporation | Compositions and Methods for Treatment of Liver Disease |
| DK4031569T3 (da) | 2019-09-16 | 2025-11-17 | Opsidio Llc | Antistoffer mod stamcellefaktor og fremgangsmåder til anvendelse deraf |
| US20240182556A1 (en) | 2021-03-17 | 2024-06-06 | Opsidio, LLC | Stem cell factor antibodies and methods of use thereof |
-
2020
- 2020-09-16 DK DK20866530.7T patent/DK4031569T3/da active
- 2020-09-16 WO PCT/US2020/050974 patent/WO2021055409A1/en not_active Ceased
- 2020-09-16 AR ARP200102566A patent/AR119979A1/es unknown
- 2020-09-16 FI FIEP20866530.7T patent/FI4031569T3/fi active
- 2020-09-16 PT PT208665307T patent/PT4031569T/pt unknown
- 2020-09-16 US US17/022,465 patent/US11939373B2/en active Active
- 2020-09-16 AU AU2020351138A patent/AU2020351138A1/en active Pending
- 2020-09-16 UA UAA202201048A patent/UA129546C2/uk unknown
- 2020-09-16 EP EP20865210.7A patent/EP4031176A4/en active Pending
- 2020-09-16 CN CN202080078693.XA patent/CN114729036B/zh active Active
- 2020-09-16 CN CN202410508865.2A patent/CN118561997A/zh active Pending
- 2020-09-16 US US17/640,544 patent/US20220324957A1/en active Pending
- 2020-09-16 EP EP25193246.3A patent/EP4650367A2/en active Pending
- 2020-09-16 PH PH1/2022/550647A patent/PH12022550647A1/en unknown
- 2020-09-16 TW TW109131936A patent/TWI875812B/zh active
- 2020-09-16 JP JP2022517136A patent/JP7698635B2/ja active Active
- 2020-09-16 MX MX2022003159A patent/MX2022003159A/es unknown
- 2020-09-16 AU AU2020348295A patent/AU2020348295A1/en active Pending
- 2020-09-16 WO PCT/US2020/050973 patent/WO2021055408A1/en not_active Ceased
- 2020-09-16 CA CA3154648A patent/CA3154648A1/en active Pending
- 2020-09-16 UY UY0001038883A patent/UY38883A/es unknown
- 2020-09-16 KR KR1020227012536A patent/KR20220079561A/ko active Pending
- 2020-09-16 TW TW114107177A patent/TW202523696A/zh unknown
- 2020-09-16 EP EP20866530.7A patent/EP4031569B1/en active Active
- 2020-09-16 JP JP2022517173A patent/JP7717687B2/ja active Active
- 2020-09-16 CA CA3154649A patent/CA3154649A1/en active Pending
- 2020-09-16 US US17/640,538 patent/US20220340655A1/en not_active Abandoned
- 2020-09-16 PE PE2022000419A patent/PE20230090A1/es unknown
- 2020-09-16 BR BR112022004776A patent/BR112022004776A2/pt unknown
-
2022
- 2022-03-15 DO DO2022000058A patent/DOP2022000058A/es unknown
- 2022-03-15 IL IL291385A patent/IL291385A/en unknown
- 2022-03-15 CL CL2022000633A patent/CL2022000633A1/es unknown
- 2022-03-16 SA SA522431966A patent/SA522431966B1/ar unknown
- 2022-03-18 ZA ZA2022/03272A patent/ZA202203272B/en unknown
- 2022-03-24 EC ECSENADI202222676A patent/ECSP22022676A/es unknown
- 2022-03-28 CO CONC2022/0003661A patent/CO2022003661A2/es unknown
- 2022-09-06 US US17/929,976 patent/US20230019680A1/en not_active Abandoned
-
2023
- 2023-11-02 US US18/500,622 patent/US12410246B2/en active Active
-
2025
- 2025-06-13 JP JP2025099435A patent/JP2025125563A/ja active Pending
- 2025-07-23 JP JP2025123268A patent/JP2025165991A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| JP2020508655A5 (fi) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| FI3826667T3 (fi) | Claudin6 vasta-aineita ja menetelmiä syövän hoitamiseksi | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| JP2020524510A5 (fi) | ||
| PE20231958A1 (es) | Moleculas de union a pd-1 y metodos de uso de las mismas | |
| JP2017504578A5 (fi) | ||
| JP2018516853A5 (fi) | ||
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2012525829A5 (fi) | ||
| JP2015504421A5 (fi) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| RU2017134495A (ru) | Антитела к альфа-рецептору собачьего интерлейкина-4 | |
| JP2010502183A5 (fi) | ||
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| RU2012137380A (ru) | Моноклональные антитела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| FI4031569T3 (fi) | Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät | |
| EA201790816A1 (ru) | Антитела, которые связываются с ccr6, и варианты применения указанных антител | |
| PE20221511A1 (es) | Anticuerpos anti-ly6g6d y metodos de uso | |
| JP2017511152A5 (fi) | ||
| JP2016529213A5 (fi) | ||
| RU2017123022A (ru) | Гуманизованные антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой тарапии |